The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2021 | Molecular testing for adenocarcinoma and squamous cell lung cancer
Sonam Puri, MD, Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT, discusses the testing procedures for the two types of non-small cell lung cancer (NSCLC). Dr. Puri speaks on the value of broad-based DNA/RNA molecular testing on any patient with metastatic adenocarcinoma at the time of diagnosis. However, this testing is limited for patients with early-stage disease. For squamous cell lung cancer, a PD-L1 test is conducted which acts as a biomarker for immunotherapy response. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
